Endocr Metab Immune Disord Drug Targets. 2021;21(7):1219-1231. doi: 10.2174/1871530320666200820092534.

Pharmacokinetic Approach of Clinically Important Drug Interactions of Hormonal Contraceptives - A Review.

Endocrine, metabolic & immune disorders drug targets

Naina M P Maideen, Rajkapoor Balasubramanian, Sambathkumar Ramanathan

PMID: 32819252 DOI: 10.2174/1871530320666200820092534

Abstract

Hormonal contraceptives contain an Estrogen and/or a Progestin, which are the substrates of the CYP3A4 enzyme and the drugs inducing the CYP3A4 enzyme can decrease the plasma concentrations and thereby therapeutic efficacy of Hormonal contraceptives resulting in unintended pregnancy. Moreover, the hormonal contraceptives associated risk of thrombotic events are further exacerbated by the simultaneous administration of drugs like Tranexamic acid and tobacco smoke. Therefore, while prescribing hormonal contraception and other drugs to women, drug interactions should always be considered because there could be a possible contraceptive failure or other adverse drug effects. This article provides a summary of guidance to healthcare professionals such as prescribers and pharmacists on pharmacokinetic based interactions between hormonal contraception and other drugs.

Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Keywords: Drug interactions; ethinyl estradiol; hormonal contraceptives; pharmacodynamic interactions.; pharmacokinetic interactions; progestin

Publication Types

• Journal Article